Income Tax Expense (Benefit) of VERTEX PHARMACEUTICALS INC / MA from 31 Dec 2010 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
VERTEX PHARMACEUTICALS INC / MA quarterly and annual Income Tax Expense (Benefit) in USD history and change rate from 31 Dec 2010 to 31 Dec 2025.
  • VERTEX PHARMACEUTICALS INC / MA Income Tax Expense (Benefit) for the quarter ending 31 Dec 2025 was $139,900,000, a 37% decline year-over-year.
  • VERTEX PHARMACEUTICALS INC / MA Income Tax Expense (Benefit) for the twelve months ending 31 Dec 2025 was $690,000,000, a 12% decline year-over-year.
  • VERTEX PHARMACEUTICALS INC / MA annual Income Tax Expense (Benefit) for 2025 was $690,000,000, a 12% decline from 2024.
  • VERTEX PHARMACEUTICALS INC / MA annual Income Tax Expense (Benefit) for 2024 was $784,100,000, a 3.1% increase from 2023.
  • VERTEX PHARMACEUTICALS INC / MA annual Income Tax Expense (Benefit) for 2023 was $760,200,000, a 16% decline from 2022.
Source SEC data
View on sec.gov
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Change (%)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Change (%)

VERTEX PHARMACEUTICALS INC / MA Quarterly Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $690,000,000 $139,900,000 -$83,600,000 -37% 01 Oct 2025 31 Dec 2025 10-K 13 Feb 2026 2025 FY
Q3 2025 $773,600,000 $215,900,000 +$37,200,000 +21% 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $736,400,000 $250,100,000 +$47,700,000 +24% 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $688,700,000 $84,100,000 -$95,400,000 -53% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $784,100,000 $223,500,000 +$44,700,000 +25% 01 Oct 2024 31 Dec 2024 10-K 13 Feb 2026 2025 FY
Q3 2024 $739,400,000 $178,700,000 +$34,800,000 +24% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025 2025 Q3
Q2 2024 $704,600,000 $202,400,000 -$43,400,000 -18% 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025 2025 Q2
Q1 2024 $748,000,000 $179,500,000 -$12,200,000 -6.4% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 $760,200,000 $178,800,000 -$79,100,000 -31% 01 Oct 2023 31 Dec 2023 10-K 13 Feb 2026 2025 FY
Q3 2023 $839,300,000 $143,900,000 -$102,000,000 -41% 01 Jul 2023 30 Sep 2023 10-Q 05 Nov 2024 2024 Q3
Q2 2023 $941,300,000 $245,800,000 +$31,900,000 +15% 01 Apr 2023 30 Jun 2023 10-Q 02 Aug 2024 2024 Q2
Q1 2023 $909,400,000 $191,700,000 -$1,000,000 -0.52% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $910,400,000 $257,900,000 +$157,100,000 +156% 01 Oct 2022 31 Dec 2022 10-K 13 Feb 2025 2024 FY
Q3 2022 $753,300,000 $245,900,000 +$15,000,000 +6.5% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $738,300,000 $213,900,000 +$325,100,000 01 Apr 2022 30 Jun 2022 10-Q 02 Aug 2023 2023 Q2
Q1 2022 $413,200,000 $192,700,000 +$24,900,000 +15% 01 Jan 2022 31 Mar 2022 10-Q 02 May 2023 2023 Q1
Q4 2021 $388,300,000 $100,800,000 -$183,633,000 -65% 01 Oct 2021 31 Dec 2021 10-K 15 Feb 2024 2023 FY
Q3 2021 $571,933,000 $230,900,000 +$152,463,000 +194% 01 Jul 2021 30 Sep 2021 10-Q 28 Oct 2022 2022 Q3
Q2 2021 $419,470,000 $111,200,000 -$98,700,000 -790% 01 Apr 2021 30 Jun 2021 10-Q 05 Aug 2022 2022 Q2
Q1 2021 $518,170,000 $167,800,000 +$113,019,000 +206% 01 Jan 2021 31 Mar 2021 10-Q 06 May 2022 2022 Q1
Q4 2020 $405,151,000 $284,433,000 +$190,717,000 +204% 01 Oct 2020 31 Dec 2020 10-K 11 Feb 2021 2020 FY
Q3 2020 $214,434,000 $78,437,000 +$65,289,000 +497% 01 Jul 2020 30 Sep 2020 10-Q 03 Nov 2021 2021 Q3
Q2 2020 $149,145,000 $12,500,000 -$72,211,000 -121% 01 Apr 2020 30 Jun 2020 10-Q 30 Jul 2021 2021 Q2
Q1 2020 $221,356,000 $54,781,000 +$3,247,000 +6.3% 01 Jan 2020 31 Mar 2020 10-Q 30 Apr 2021 2021 Q1
Q4 2019 $218,109,000 $93,716,000 +$1,586,315,000 01 Oct 2019 31 Dec 2019 10-K 11 Feb 2021 2020 FY
Q3 2019 $1,368,206,000 $13,148,000 +$5,093,000 +63% 01 Jul 2019 30 Sep 2019 10-K 11 Feb 2021 2020 FY
Q2 2019 $1,373,299,000 $59,711,000 +$49,370,000 +477% 01 Apr 2019 30 Jun 2019 10-K 11 Feb 2021 2020 FY
Q1 2019 $1,422,669,000 $51,534,000 +$64,193,000 01 Jan 2019 31 Mar 2019 10-K 11 Feb 2021 2020 FY
Q4 2018 $1,486,862,000 $1,492,599,000 -$1,502,856,000 -14652% 01 Oct 2018 31 Dec 2018 10-K 13 Feb 2020 2019 FY
Q3 2018 $15,994,000 $8,055,000 +$133,958,000 01 Jul 2018 30 Sep 2018 10-K 13 Feb 2020 2019 FY
Q2 2018 $117,964,000 $10,341,000 +$6,004,000 +138% 01 Apr 2018 30 Jun 2018 10-K 13 Feb 2020 2019 FY
Q1 2018 $123,968,000 $12,659,000 -$16,644,000 -418% 01 Jan 2018 31 Mar 2018 10-K 13 Feb 2020 2019 FY
Q4 2017 $107,324,000 $10,257,000 +$17,710,000 01 Oct 2017 31 Dec 2017 10-K 13 Feb 2019 2018 FY
Q3 2017 $125,034,000 $125,903,000 -$126,406,000 -25130% 01 Jul 2017 30 Sep 2017 10-K 13 Feb 2019 2018 FY
Q2 2017 $1,372,000 $4,337,000 -$13,793,000 -76% 01 Apr 2017 30 Jun 2017 10-K 13 Feb 2019 2018 FY
Q1 2017 $15,165,000 $3,985,000 -$1,500,000 -27% 01 Jan 2017 31 Mar 2017 10-K 13 Feb 2019 2018 FY
Q4 2016 $16,665,000 $7,453,000 -$6,074,000 -440% 01 Oct 2016 31 Dec 2016 10-K 15 Feb 2018 2017 FY
Q3 2016 $22,739,000 $503,000 -$827,000 -62% 01 Jul 2016 30 Sep 2016 10-K 15 Feb 2018 2017 FY
Q2 2016 $23,566,000 $18,130,000 -$12,001,000 -40% 01 Apr 2016 30 Jun 2016 10-K 15 Feb 2018 2017 FY
Q1 2016 $35,567,000 $5,485,000 +$5,186,000 +1734% 01 Jan 2016 31 Mar 2016 10-K 15 Feb 2018 2017 FY
Q4 2015 $30,381,000 $1,379,000 -$3,422,000 -167% 01 Oct 2015 31 Dec 2015 10-K 23 Feb 2017 2016 FY
Q3 2015 $33,803,000 $1,330,000 -$2,089,000 -61% 01 Jul 2015 30 Sep 2015 10-K 23 Feb 2017 2016 FY
Q2 2015 $35,892,000 $30,131,000 +$29,438,000 +4248% 01 Apr 2015 30 Jun 2015 10-K 23 Feb 2017 2016 FY
Q1 2015 $6,454,000 $299,000 -$504,000 -63% 01 Jan 2015 31 Mar 2015 10-K 23 Feb 2017 2016 FY
Q4 2014 $6,958,000 $2,043,000 +$691,000 +51% 01 Oct 2014 31 Dec 2014 10-K 16 Feb 2016 2015 FY
Q3 2014 $6,267,000 $3,419,000 +$864,000 +34% 01 Jul 2014 30 Sep 2014 10-K 16 Feb 2016 2015 FY
Q2 2014 $5,403,000 $693,000 +$135,000 +24% 01 Apr 2014 30 Jun 2014 10-K 16 Feb 2016 2015 FY
Q1 2014 $5,268,000 $803,000 +$127,690,000 01 Jan 2014 31 Mar 2014 10-K 16 Feb 2016 2015 FY
Q4 2013 $122,422,000 $1,352,000 +$4,048,000 01 Oct 2013 31 Dec 2013 10-K 13 Feb 2015 2014 FY
Q3 2013 $126,470,000 $2,555,000 -$18,800,000 -88% 01 Jul 2013 30 Sep 2013 10-K 13 Feb 2015 2014 FY
Q2 2013 $107,670,000 $558,000 -$19,505,000 -97% 01 Apr 2013 30 Jun 2013 10-K 13 Feb 2015 2014 FY
Q1 2013 $88,165,000 $126,887,000 -$158,887,000 -497% 01 Jan 2013 31 Mar 2013 10-K 13 Feb 2015 2014 FY
Q4 2012 $70,722,000 $2,696,000 -$25,356,000 -112% 01 Oct 2012 31 Dec 2012 10-K 11 Feb 2014 2013 FY
Q3 2012 $96,078,000 $21,355,000 +$49,197,000 01 Jul 2012 30 Sep 2012 10-K 11 Feb 2014 2013 FY
Q2 2012 $46,881,000 $20,063,000 -$4,385,000 -18% 01 Apr 2012 30 Jun 2012 10-K 11 Feb 2014 2013 FY
Q1 2012 $51,266,000 $32,000,000 +$32,000,000 01 Jan 2012 31 Mar 2012 10-K 11 Feb 2014 2013 FY
Q4 2011 $19,266,000 $22,660,000 01 Oct 2011 31 Dec 2011 10-K 01 Mar 2013 2012 FY
Q3 2011 $27,842,000 01 Jul 2011 30 Sep 2011 10-K 01 Mar 2013 2012 FY
Q2 2011 $24,448,000 01 Apr 2011 30 Jun 2011 10-K 01 Mar 2013 2012 FY
Q1 2011 $0 01 Jan 2011 31 Mar 2011 10-K 01 Mar 2013 2012 FY

VERTEX PHARMACEUTICALS INC / MA Annual Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $690,000,000 -$94,100,000 -12% 01 Jan 2025 31 Dec 2025 10-K 13 Feb 2026 2025 FY
2024 $784,100,000 +$23,900,000 +3.1% 01 Jan 2024 31 Dec 2024 10-K 13 Feb 2026 2025 FY
2023 $760,200,000 -$150,200,000 -16% 01 Jan 2023 31 Dec 2023 10-K 13 Feb 2026 2025 FY
2022 $910,400,000 +$522,100,000 +134% 01 Jan 2022 31 Dec 2022 10-K 13 Feb 2025 2024 FY
2021 $388,300,000 -$16,900,000 -4.2% 01 Jan 2021 31 Dec 2021 10-K 15 Feb 2024 2023 FY
2020 $405,200,000 +$187,100,000 +86% 01 Jan 2020 31 Dec 2020 10-K 10 Feb 2023 2022 FY
2019 $218,100,000 +$1,704,962,000 01 Jan 2019 31 Dec 2019 10-K 09 Feb 2022 2021 FY
2018 $1,486,862,000 -$1,379,538,000 -1285% 01 Jan 2018 31 Dec 2018 10-K 11 Feb 2021 2020 FY
2017 $107,324,000 -$123,989,000 -744% 01 Jan 2017 31 Dec 2017 10-K 13 Feb 2020 2019 FY
2016 $16,665,000 -$13,716,000 -45% 01 Jan 2016 31 Dec 2016 10-K 13 Feb 2019 2018 FY
2015 $30,381,000 +$23,423,000 +337% 01 Jan 2015 31 Dec 2015 10-K 15 Feb 2018 2017 FY
2014 $6,958,000 +$129,380,000 01 Jan 2014 31 Dec 2014 10-K 23 Feb 2017 2016 FY
2013 $122,422,000 -$122,147,000 -44417% 01 Jan 2013 31 Dec 2013 10-K 16 Feb 2016 2015 FY
2012 $275,000 -$19,541,000 -101% 01 Jan 2012 31 Dec 2012 10-K 13 Feb 2015 2014 FY
2011 $19,266,000 +$19,266,000 01 Jan 2011 31 Dec 2011 10-K 11 Feb 2014 2013 FY
2010 $0 01 Jan 2010 31 Dec 2010 10-K 01 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.